ストックスクリーナーアプリを入手
26.20
0.73%
0.19
アフターアワーズ：
26.29
0.09
+0.34%
前日終値:
$26.01
開ける：
$26.09
24時間の取引高:
2.22M
Relative Volume:
0.60
時価総額：
$19.46B
収益：
$956.00K
当期純損益:
$-221.32M
株価収益率:
-81.88
EPS:
-0.32
ネットキャッシュフロー:
$-142.25M
1週間 パフォーマンス:
-1.84%
1か月 パフォーマンス:
-1.28%
6か月 パフォーマンス:
+18.44%
1年 パフォーマンス:
+93.79%
1日の値動き範囲:
$25.80
$27.00
1週間の範囲:
$24.77
$27.00
52週間の値動き範囲:
$11.76
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
SMMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
26.20 | 19.53B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-01 | 開始されました | UBS | Buy |
| 2025-06-11 | 開始されました | Leerink Partners | Underperform |
| 2025-03-26 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | Goldman | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Summit stock gets Neutral view at Piper Sandler (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics: JMP Securities Raises PT to $40, Maintains Market Outperform Rating - AInvest
Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism - MSN
Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target - MarketScreener
Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call - MSN
Top 3 Growth Stocks to Buy in August: Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals - AInvest
3 Fantastic Growth Stocks to Buy in August - The Globe and Mail
Does Summit Therapeutics Inc. show high probability of rebound2025 Top Gainers & Community Verified Swing Trade Signals - Newser
What is the dividend yield of Summit Therapeutics Inc.2025 Earnings Surprises & Reliable Breakout Stock Forecasts - thegnnews.com
Is it too late to sell Summit Therapeutics Inc.Day Trade & Free Weekly Watchlist of Top Performers - Newser
Cantor Fitzgerald Has Weak Outlook for SMMT FY2025 Earnings - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns “Buy” Rating from HC Wainwright - Defense World
Summit Therapeutics Inc.’s Beta Climbs After Market VolatilityMarket Sentiment Report & Consistent Profit Trade Alerts - metal.it
Summit Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - Newser
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - MSN
What makes Summit Therapeutics Inc. stock price move sharplySwing Trade & Smart Investment Allocation Insights - thegnnews.com
How to build a dashboard for Summit Therapeutics Inc. stock2025 Market WrapUp & Expert-Curated Trade Recommendations - Newser
11 Best Short Squeeze Stocks to Buy Now - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Downgraded to Sell Rating by Wall Street Zen - Defense World
Pattern recognition hints at Summit Therapeutics Inc. upsidePortfolio Gains Report & Proven Capital Preservation Methods - Newser
SVP, US Marketing at Summit Therapeutics Inc. Job - Mediabistro
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday - MSN
Strategies to average down on Summit Therapeutics Inc.July 2025 Fed Impact & Real-Time Market Trend Scan - Newser
Summit Therapeutics Faces Questions Over Its Cash Burn And Future - Finimize
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 - Stock Titan
Custom Dashboard Highlights Summit Therapeutics Inc. Price MomentumJuly 2025 Technicals & Reliable Intraday Trade Plans - beatles.ru
Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says - 富途牛牛
Why Summit Therapeutics Shares Are Poised for Growth - TipRanks
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $33 to $35 - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Glaukos (GKOS) - The Globe and Mail
Evercore ISI Issues Positive Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock Price - Defense World
Summit Therapeutics shares rise 2.16% premarket after earnings results reported. - AInvest
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 - The Globe and Mail
10 Stocks That Vanished in Value - Insider Monkey
Summit Therapeutics’ Promising Advancements in Cancer Treatment Drive Buy Rating - TipRanks
SMMT Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Positive Outlook for Summit Therapeutics: Buy Rating Supported by Financial Stability and Strategic Developments - TipRanks
Summit Therapeutics notes ‘doubt’ about ability to continue as ‘going concern’ - TipRanks
Summit Therapeutics Plummets 11.9% Amid Legal Storm: What’s Brewing in Biotech? - AInvest
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus - Nasdaq
Summit Therapeutics price target raised to $33 from $30 at Clear Street - TipRanks
Evercore ISI Group Raises Summit Therapeutics PT to $34, Maintains Outperform Rating - AInvest
Summit Therapeutics stock price target raised to $34 by Evercore ISI - Investing.com Canada
Summit Therapeutics shares fall 3.72% premarket after reporting Q2 financial results and operational updates. - AInvest
Summit Therapeutics Inc. Securities Fraud LawsuitClass Action Opportunity - AInvest
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Summit Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Summit Therapeutics Q2 Loss Widens to $0.12 per Share - AInvest
Summit Therapeutics Q2 Adjusted Loss Widens - MarketScreener
Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus
Summit Therapeutics Amends Stock Distribution Agreement - TipRanks
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
Summit Therapeutics Inc (SMMT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
1.72%
0.94%
大文字化:
|
ボリューム (24 時間):